SOPHiA GENETICS (NASDAQ:SOPH) Stock: Insider Jurgi Camblong Sells 8,500 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) Chairman Jurgi Camblong sold 8,500 shares of the company’s stock in a transaction dated Monday, October 12th. The stock was sold at an average price of $7.26, for a total value of $61,710.00. Following the completion of the transaction, the chairman directly owned 3,387,150 shares of the company’s stock, valued at approximately $24,590,709. This trade represents a 0.25% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jurgi Camblong also recently made the following trade(s):

• On Monday, October 5th, Jurgi Camblong sold 40,172 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $8.13, for a total value of $326,598.36.
• On Thursday, September 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.66, for a total value of $65,110.00.
• On Monday, August 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.61, for a total value of $64,685.00.
• On Friday, August 7th, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.23, for a total value of $144,600.00.
• On Tuesday, August 4th, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.92, for a total value of $138,400.00.
• On Tuesday, July 21st, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.63, for a total transaction of $132,600.00.
• On Monday, July 20th, Jurgi Camblong sold 24,381 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.29, for a total transaction of $153,356.49.

SOPHiA GENETICS Price Performance

Shares of SOPHiA GENETICS stock traded down $0.03 on Wednesday, hitting $7.06. 376,763 shares of the company traded hands, compared to its average volume of 310,258. The stock has a market capitalization of $592.26 million, a P/E ratio of -6.14 and a beta of 0.95. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. SOPHiA GENETICS SA has a 52 week low of $3.75 and a 52 week high of $8.98. The business has a 50-day simple moving average of $7.95 and a 200 day simple moving average of $6.20.

SOPHiA GENETICS (NASDAQ:SOPH) last released its earnings results on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. The company had revenue of $23.31 million during the quarter, compared to analysts’ expectations of $21.72 million. Research analysts expect that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

SOPH has been the subject of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 target price on shares of SOPHiA GENETICS in a report on Monday. Zacks Research upgraded SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. Finally, BTIG Research increased their price target on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $10.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of SOPH. Silverberg Bernstein Capital Management LLC lifted its position in SOPHiA GENETICS by 8.7% during the first quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock valued at $257,000 after purchasing an additional 4,155 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in shares of SOPHiA GENETICS by 0.7% in the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after acquiring an additional 9,800 shares during the last quarter. First Dallas Securities Inc. purchased a new position in SOPHiA GENETICS in the first quarter worth about $50,000. 1492 Capital Management LLC increased its stake in SOPHiA GENETICS by 8.4% during the first quarter. 1492 Capital Management LLC now owns 225,751 shares of the company’s stock worth $1,117,000 after acquiring an additional 17,406 shares during the last quarter. Finally, Royal Bank of Canada increased its stake in SOPHiA GENETICS by 3,130.2% during the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after acquiring an additional 18,781 shares during the last quarter. 31.59% of the stock is owned by hedge funds and other institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.